Karolinska Development portfolio company Promimic AB appoints Magnus Larsson as new CEO and launches US sales operation
January 18, 2017 02:00 ET
|
Karolinska Development AB
Details from the Promimic announcement follow:
Magnus Larsson has a solid background in Sales and Marketing, having held a number of leadership positions in the international dental...
Aprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco
January 05, 2017 02:00 ET
|
Karolinska Development AB
About Aprea Therapeutics AB
Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer...
Karolinska Development portfolio company Dilafor initiates Phase IIb clinical trial with tafoxiparin in women with protracted labor
January 04, 2017 02:00 ET
|
Karolinska Development AB
Details from the Dilafor press release follow:
Tafoxiparin is in clinical development as a new treatment designed to decrease the incidence of protracted labor (i.e labor that lasts more...
Karolinska Development portfolio company Dilafor AB granted U.S. patent for Phase II drug tafoxiparin
December 02, 2016 02:00 ET
|
Karolinska Development AB
Details from the Dilafor press release follow:
Tafoxiparin is in clinical development as a new treatment designed to decrease the incidence of protracted labor both after induction of...
Karolinska Development company Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego
December 01, 2016 02:00 ET
|
Karolinska Development AB
Details from the Modus Therapeutics press release follow:
The poster entitled: Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose...
Karolinska Development: Interim Report for January-September 2016
November 23, 2016 01:50 ET
|
Karolinska Development AB
Jim Van heusden, CEO, comments: “During the third quarter 2016, Karolinska Development saw several of its portfolio companies secure new funds to finance the progression of their businesses toward...
Karolinska Development: Delårsrapport för januari - september 2016
November 23, 2016 01:50 ET
|
Karolinska Development AB
Jim Van heusden, CEO, kommenterar: “Under tredje kvartalet 2016 har flera av Karolinska Developments portföljbolag säkrat ny finansiering för att utveckla verksamheten mot sina definierade...
Karolinska Development company Umecrine Cognition raises SEK 45 million to advance GR3027, a novel drug candidate for hepatic encephalopathy
November 22, 2016 02:00 ET
|
Karolinska Development AB
Details from the Umecrine Cognition press release follow:
Hepatic encephalopathy (HE) is a serious brain disorder and one of the primary complications in acute and chronic liver disease....
Karolinska Development – Delårsrapport för januari - september 2016, inbjudan till telefonkonferens och webbpresentation
November 17, 2016 02:19 ET
|
Karolinska Development AB
Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start:
Från Sverige: +46 (0) 8 505 564 74
Från USA: +1 855 753 22 30
Från Storbritannien: +44...
Karolinska Development – Delårsrapport för januari - september 2016, inbjudan till telefonkonferens och webbpresentation
November 17, 2016 02:00 ET
|
Karolinska Development AB
Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start:
Från Sverige: +46 (0) 8 505 564 74
Från USA: +1 855 753 22 30
Från Storbritannien: +44...